Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticleukaemia treated with ibrutinib from 3 clinical trials
Jeffrey Jones, Anthony Mato, Steven Coutre, John C Byrd, Richard R Furman, Peter Hillmen, Anders Osterborg, Constantine Tam, Stephan Stilgenbauer, William G Wierda, Nyla A Heerema, Karl Eckert, Fong Clow, Cathy Zhou, Alvina D Chu, Danelle F James, Susan M O'Brien
British Journal of Haematology | WILEY | Published : 2018
Patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) with deletion 17p [del(17p)] have poor outcomes with chemoimmunotherapy. Ibrutinib is indicated for the treatment of CLL/SLL, including del(17p) CLL/SLL, and allows for treatment without chemotherapy. This integrated analysis was performed to evaluate outcomes in 230 patients with relapsed/refractory del(17p) CLL/SLL from three ibrutinib studies. With a median of 2 prior therapies (range, 1-12), 18% and 79% of evaluable patients had del(11q) or unmutated IGHV, respectively. With a median follow-up of 28 months, overall response rate was 85% and estimated 30-month progression-free and overall survival rates were ..View full abstract
We thank the patients who participated in these studies, their supporters, and the investigators and clinical research staff from the study centres. This manuscript was developed with editorial support from Stacey Rose, PhD, and funded by Pharmacyclics LLC, an AbbVie Company.